Kymera Therapeutics Stock (NASDAQ:KYMR)
Previous Close
$76.91
52W Range
$36.65 - $103.00
50D Avg
$82.86
200D Avg
$72.02
Market Cap
$6.44B
Avg Vol (3M)
$565.02K
Beta
2.03
Div Yield
-
KYMR Company Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AAPG | Ascentage Pharma Group International |
| VKTX | Viking Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| AKRO | Akero Therapeutics, Inc. |
| IMVT | Immunovant, Inc. |